# Frontier IP Group The Vaccine Group wins Department of Health grant

- Link: https://www.directorstalkinterviews.com/frontier-ip-group-the-vaccine-group-wins-department-of-health-grant/412765429
- Published: 2019-01-25T07:07:10+00:00
- Author: Giles Arbor

**Frontier IP Group** (LON: FIPP), a specialist in commercialising university intellectual
property, has today announced portfolio company The Vaccine Group, has won a £403,000
grant as part of a £1.46 million Anglo-Chinese project to combat an emerging antibiotic-
resistant disease able to jump from pigs to humans with potentially fatal effect.

The project, funded by the Department of Health and Social Care (DHSC) and administered
by Innovate UK, will develop TVG’s novel herpesvirus-based platform technology to
create a single-use vaccine for use in pigs. The work will be undertaken with Chinese
partners, including the Shanghai Veterinary Research Institute at the Chinese Academy
of Agricultural Science, and the Shanghai Jiao Tong University. A major producer
of swine and poultry vaccines, the Pulike Biological Engineering Company, is the
commercial partner.

The vaccine will target a bacterium called Streptococcus suis (S.suis), which can
cause meningitis, blood poisoning, or septicaemia, as well as many other serious
diseases in humans. Incidents have been rising globally and in Asia it is now classified
as an emerging threat. The disease is currently treated with antibiotics, but there
is growing evidence that S.suis is becoming resistant to them. Effective vaccines
remove the need to use antibiotics in animals.

The University of Plymouth spin out was founded by Dr Michael Jarvis, Associate 
Professor of Immunology and Virology at the university’s Institute of Translational
and Stratified Medicine. Frontier IP holds a 19.2 per cent stake in the Company.

TVG’s technology is based on safe forms of herpesviruses, which occur in nearly 
all animals, including humans. The vaccines are created by modifying these viruses
through inserting regions of the pathogen being targeted to stimulate immune responses
against the disease.

The grant was awarded as part a bilateral research competition between the DHSC’s
Global antimicrobial resistance (AMR) Innovation Fund and the Chinese Ministry of
Science and Technology: UK-China partnerships against antimicrobial resistance get
funding

A review by economist Lord O’Neill estimated that AMR caused 700,000 deaths each
year globally.

> **Professor Dame Sally Davies, England’s Chief Medical Officer, said: **
> “Drug resistant infections claim hundreds of thousands of lives across the globe.
> An innovative and international response is vital – this latest collaboration 
> between the UK and China guarantees much needed research to address the complex
> and world-wide issue of AMR.”
> **Dr Kath Mackay, Interim Director – Ageing Society, Health & Nutrition, Innovate
> UK said: **
> “Antimicrobial resistance is one of the biggest global challenges in healthcare.
> It has been estimated that the AMR threat could lead to 10 million extra deaths
> a year and cost the global economy up to £75 trillion by 2050.
> This partnership between China and the UK’s world-leading bio-industry is a vital
> contribution to tacking this issue through international co-operation.”
> **TVG founder and director Associate Professor Michael Jarvis said: **
> “Vaccination to control bacterial diseases has been shown to be really effective
> in the fish industry, and it does this without increasing bacterial resistance
> to antibiotics (AMR). We’re therefore very excited about the opportunity this 
> grant gives to expand this approach to a major bacterial disease of pigs that 
> is increasingly being spread to humans.
> AMR and emerging infectious disease are global problems, and this grant also demonstrates
> the strength of bringing together scientists and stakeholders from across the 
> globe to address common societal issues.
> This exciting development supports the novel approach The Vaccine Group has towards
> creating new vaccines to combat the spread of dangerous diseases from one animal
> species to another.”
> **Frontier IP Group chief executive officer Neil Crabb said: **
> “TVG’s novel vaccine technology has the potential to play a material role in beating
> the threats of antimicrobial resistance and, more widely, from life-threatening
> diseases which infect animals and then jump to humans.”

Share on:
